Transgene SA (EPA:TNG)
France · Delayed Price · Currency is EUR 0.7400
-0.0260 (-3.39%)
Apr 2, 2026, 5:35 PM CET
Transgene Market Cap
Transgene has a market cap or net worth of €202.63 million as of April 2, 2026. Its market cap has increased by 131.55% in one year.
Market Cap
202.63M
Enterprise Value
92.83M
Revenue
7.21M
Ranking
n/a
PE Ratio
n/a
Stock Price
€0.74
Market Cap Chart
Since March 30, 1998, Transgene's market cap has increased from 151.86M to 202.63M, an increase of 33.43%. That is a compound annual growth rate of 1.03%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 2, 2026 | 202.63M | -22.92% |
| Dec 31, 2025 | 262.87M | 192.89% |
| Dec 31, 2024 | 89.75M | -34.86% |
| Dec 29, 2023 | 137.78M | -16.38% |
| Dec 30, 2022 | 164.76M | -33.52% |
| Dec 31, 2021 | 247.84M | 79.73% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| MedinCell | 829.39M |
| Valneva SE | 470.87M |
| Genfit | 429.73M |
| Cellectis | 225.40M |
| Sensorion | 215.15M |
| ABIONYX Pharma | 130.35M |
| MaaT Pharma | 107.63M |
| Innate Pharma | 105.35M |